Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
New drug for intestinal fibrosis

Researchers from Ghent University Hospital have forced a breakthrough in the fight against intestinal fibrosis, a complication that occurs especia…


Cell therapy for Crohn's disease gets FDA boost to enter US market

TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of al…

POPULAR TAGS

New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

Written by DS on in the category news with the tags , .


Galapagos NV announced two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being led by filgotinib collaboration partner Gilead Sciences, Inc.

The first additional Crohn's disease Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of the investigational selective JAK1 inhibitor filgotinib in adult patients with small bowel Crohn's disease. Approximately 100 patients in North America and Europe are planned to be randomized in the study to receive one of two doses of filgotinib or placebo, administered for 24 weeks. The primary objective will be to compare filgotinib to placebo in establishing clinical remission, defined as CDAI<150, in patients with small bowel Crohn's disease at week 24.

The second Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients with perianal fistulizing Crohn's disease. Approximately 75 patients are planned to be randomized in the study to receive one of two doses of filgotinib or placebo administered for 24 weeks. The primary objective is to evaluate the efficacy of filgotinib, compared to placebo, in establishing a combined fistula response at week 24.

Eligible patients who complete either study may be able to continue in a long term extension study.

These new Phase 2 studies with filgotinib follow the initiation of the DIVERSITY Phase 3 study in Crohn's disease. Gilead further initiated the FINCH Phase 3 program in rheumatoid arthritis and the SELECTION Phase 2b/3 study in ulcerative colitis in 2016.

Read more about: , .

RELATED ARTICLES
New drug for intestinal fibrosis

Researchers from Ghent University Hospital have forced a breakthrough in the fight against intestinal fibrosis, a complication that occurs especia…


Cell therapy for Crohn's disease gets FDA boost to enter US market

TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of al…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

V-Bio Ventures Turnstone Janssen GSK UGent Biowin Itera Life Science Flanders.bio KU Leuven XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.